Jiajun Ye

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Coronavirus Disease

Monoclonal Antibody

Computed Tomography

Top Venues

Molecular pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Tingting Han, Zhiyong Quan, Min Wang, Xiaoli Meng, Mingru Zhang, Jiajun Ye, Guiyu Li, Jing Wang, Fei Kang
Head-to-Head Comparison of 68 Ga-PSMA-11 with 68 Ga-P137 in Patients with Suspected Prostate Cancer. Molecular pharmaceutics (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics 20 (3) (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics 20 (3) (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics 20 (3) (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics (2023)